- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04984902
Reduction of BK Viremia in Kidney Transplant Patients (CP026)
Reduction of BK Viremia in Kidney Transplant Patients Using the Seraph 100 Microbind® Affinity (Seraph 100) Blood Filter
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
a clinical investigation plan (CIP) for the "Reduction of BK viremia in kidney transplant patients using the Seraph 100 Microbind® Affinity (Seraph 100) Blood Filter" clinical study, where BK is an abbreviation of the name of the first patient whom the virus was isolated from in 1971. This clinical study is intended to evaluate the reduction of BK viremia by treating kidney transplant patients with the Seraph 100 Microbind® Affinity Blood Filter from ExThera Medical. This clinical study is sponsored by ExThera Medical Corporation.
This clinical study will be conducted in accordance with this CIP. All parties involved in the conduct of the clinical study will be qualified by education, training, or experience to perform their tasks and this training will be documented appropriately.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Carla Kikken-Jussen
- Telefonnummer: +31 43 8200 399
- E-post: carla@extheramedical.com
Studiesteder
-
-
-
Essen, Tyskland
- University Hospital Essen
-
Ta kontakt med:
- Bartosz Tyczynski, Dr.
-
Hovedetterforsker:
- Bartosz Tyczynski, Dr.
-
Ta kontakt med:
- Kristina Boss, Dr.
-
Underetterforsker:
- Kristina Boss, Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Kidney transplant patients with a BK-viraemia ≥ 10,000 IU/ml.
- Be ≥ 18 years old and ≤ 90 years old
- Existing hemodialysis access
Exclusion Criteria:
- Subject is currently participating in another clinical investigation
- Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
- Presence of comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Have Child-Pugh Class C cirrhosis
- Have platelet count <30.000/uL
- Contraindications for heparin sodium for injection
- Subjects demonstrating any contraindication for this treatment as described in the IFU
- Patients without existing hemodialysis access
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment
Treatment with Microbind® Affinity Blood Filter
|
Extracorporal therapy
|
Ingen inngripen: Control
Antibiotics
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in log 10 viral load
Tidsramme: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Time-weighted change from baseline in log10 viral load within five days after first treatment.
|
At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of participants with leukopenia
Tidsramme: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with leukopenia
|
At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with increase in serum creatinine
Tidsramme: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with increase in serum creatinine between the treatment days
|
At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with inoperative hypotension
Tidsramme: At 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with inoperative hypotension per treatment period
|
At 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with decreasing haemoglobin measurements
Tidsramme: At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Number of participants with decreasing haemoglobin measurements per treatment period
|
At day 0 and the following 3 treatments within five days after beginning with the first treatment.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
N (%) of patients with treatment emergent adverse events
Tidsramme: 2 months
|
N (%) of patients with treatment emergent adverse events
|
2 months
|
Laboratory data
Tidsramme: 2 months
|
Laboratory data (Blood test, Hematology, chemistry and coagulation)
|
2 months
|
Vital signs score
Tidsramme: 2 months
|
Vital signs score
|
2 months
|
Physical examination score
Tidsramme: 2 months
|
Physical examination score
|
2 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Bartosz Tyczynski, Dr., University Hospital, Essen
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CP026
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-deling Støtteinformasjonstype
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyresykdommer
-
Medical University of ViennaFullførtSekundær hyperparathyroidisme | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NyreerstatningØsterrike
Kliniske studier på Extracorporal therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RekrutteringPerifer nevropatiForente stater
-
VA Pacific Islands Health Care SystemUnited States Department of Defense; Charles River AnalyticsFullførtSinne | Stresslidelser, posttraumatiskForente stater
-
Douglas MenninWeill Medical College of Cornell University; Kent State UniversityFullførtGeneralisert angstlidelse | Depresjon, angst | Angstlidelser og symptomer | Emosjonell dysfunksjonForente stater
-
Cyberonics, Inc.PRA Health SciencesFullførtEpilepsiNorge, Tyskland, Storbritannia, Belgia, Nederland
-
University of PennsylvaniaAvsluttetTilbakevendende Clostridium Difficile-infeksjonForente stater
-
Utah State UniversityUkjent
-
EP SciencesUkjentHjerteelektrofysiologiForente stater
-
Loma Linda UniversityRekrutteringDiabetisk nevropati, distal symmetrisk polynevropati (manifestasjon)Forente stater
-
Mayo ClinicRekruttering
-
Azienda Ospedaliera Universitaria Integrata VeronaFullført